

M53-A
Vol. 31 No. 13
Replaces M53-P
Vol. 30 No. 21

Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection; Approved Guideline

This document provides guidance for laboratorians performing human immunodeficiency virus testing and for the interpretation of results by health care providers in advanced diagnostic laboratories.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.



Clinical and Laboratory Standards Institute

Advancing Quality in Health Care Testing

Clinical and Laboratory Standards Institute (CLSI) is an international, interdisciplinary, nonprofit, standards developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the health care community. We are recognized worldwide for the application of our unique consensus process in the development of standards and guidelines for patient testing and related health care issues. Our process is based on the principle that consensus is an effective way to improve patient testing and health care services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, we provide an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

PUBLICATIONS

A document is published as a standard, guideline, or report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the appropriate consensus committee.

CONSENSUS PROCESS

CLSI's voluntary consensus process establishes formal criteria for the following:

- Authorization of a project
- Development and open review of documents
- Revision of documents in response to users' comments
- Acceptance of a document as a consensus standard or guideline

Invitation for Participation in the Consensus Process

Core to the development of all CLSI documents is the consensus process. Within the context and operation of CLSI, voluntary consensus is substantial agreement by materially affected, competent, and interested parties that may be obtained by following the consensus procedures defined in

CLSI's Administrative Procedures. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and are willing to accept the resulting agreement. CLSI documents are expected to undergo evaluation and modification in order to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

Comments on Draft Documents

CLSI's voluntary consensus process depends on experts who serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate. All comments along with the committee's responses are retained on file at CLSI and are available upon request.

Comments on Published Documents

The comments of users of published CLSI documents are essential to the consensus process. Anyone may submit a comment. All comments are addressed according to the consensus process by a committee of experts. A summary of comments and committee responses is retained on file at CLSI and is available upon request. Readers are strongly encouraged to comment at any time on any document.

APPEALS PROCESS

CLSI consensus procedures include an appeals process that is described in detail in Section 8 of the Administrative Procedures.

VOLUNTEER PARTICIPATION

Health care professionals in all specialties are urged to volunteer for participation in CLSI projects.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
940 West Valley Road, Suite 1400
Wayne, PA 19087 USA
610.688.0100
F: 610.688.0700
www.clsi.org
standard@clsi.org

M53-A

ISBN 1-56238-757-X (Print)

ISBN 1-56238-758-8 (Electronic)

Volume 31 Number 13

ISSN 0273-3099

Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection; Approved Guideline

Eric S. Rosenberg, MD
Catherine A. Brennan, PhD
Christiane Claessens, MSc
Niel T. Constantine, PhD
Gary Murphy, PhD
S. Michele Owen, PhD
Barbara G. Werner, PhD
Joseph D.C. Yao, MD
Belinda Yen-Lieberman, PhD
Bernard M. Branson, MD
Patricia E. Garrett, PhD
Renée M. Howell, PhD

Abstract

The accurate diagnosis of human immunodeficiency virus (HIV) infection is essential for limiting the spread of infection and for the appropriate clinical management of persons infected with HIV. Over the past several years, numerous tests and testing strategies have been developed and are used by laboratorians and clinicians to diagnose HIV infection. CLSI document M53-A, *Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection; Approved Guideline*, provides an extensive review of existing laboratory methods commonly used to test for HIV infection. This guideline also offers recommendations for how to best use and interpret these tests accurately and effectively to diagnose HIV infection.

Clinical and Laboratory Standards Institute (CLSI). *Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection; Approved Guideline*. CLSI document M53-A (ISBN 1-56238-757-X [Print]; ISBN 1-56238-758-8 [Electronic]). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA, 2011.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org



Copyright ©2011 Clinical and Laboratory Standards Institute. Except as stated below, neither this publication nor any portion thereof may be adapted, copied, or otherwise reproduced, by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from Clinical and Laboratory Standards Institute ("CLSI").

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, contact the Executive Vice President, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087, USA.

Suggested Citation

CLSI. *Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection; Approved Guideline*. CLSI document M53-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.

Proposed Guideline

October 2010

Approved Guideline

June 2011

ISBN 1-56238-757-X (Print)
ISBN 1-56238-758-8 (Electronic)
ISSN 0273-3099

Committee Membership

Consensus Committee on Microbiology

John H. Rex, MD, FACP

Chairholder

AstraZeneca

Waltham, Massachusetts, USA

Mary Jane Ferraro, PhD, MPH

Vice-Chairholder

Massachusetts General Hospital

Boston, Massachusetts, USA

Nancy L. Anderson, MMSc,

MT(ASCP)

Centers for Disease Control and

Prevention

Atlanta, Georgia, USA

Barbara Ann Body, PhD, D(ABMM)

Laboratory Corporation of America

Burlington, North Carolina, USA

Betty A. Forbes, PhD, D(ABMM)

Medical College of Virginia Campus

Richmond, Virginia, USA

Thomas R. Fritsche, MD, PhD

Marshfield Clinic

Marshfield, Wisconsin, USA

Freddie Mae Poole

FDA Center for Devices and

Radiological Health

Silver Spring, Maryland, USA

Fred C. Tenover, PhD,

D(ABMM)

Cepheid

Sunnyvale, California, USA

John D. Turnidge, MD

SA Pathology at Women's

and Children's Hospital

North Adelaide, Australia

Document Development Committee on Laboratory Testing and Diagnosis of HIV-1 Infection

Eric S. Rosenberg, MD

Chairholder

Massachusetts General Hospital

Boston, Massachusetts, USA

Catherine A. Brennan, PhD

Abbott Diagnostics

Abbott Park, Illinois, USA

Christiane Claessens, MSc

Laboratoire de Santé Publique du

Québec

Ste-Anne de Bellevue, Quebec,

Canada

Niel T. Constantine, PhD

University of Maryland School of

Medicine

Baltimore, Maryland, USA

Gary Murphy, PhD

Health Protection Agency

Colindale, London, United

Kingdom

S. Michele Owen, PhD

Centers for Disease Control and

Prevention

Atlanta, Georgia, USA

Barbara G. Werner, PhD

MA Department of Public Health

Boston, Massachusetts, USA

Joseph D.C. Yao, MD

Mayo Clinic

Rochester, Minnesota, USA

Belinda Yen-Lieberman, PhD

Cleveland Clinic

Cleveland, Ohio, USA

Staff

Clinical and Laboratory Standards

Institute

Wayne, Pennsylvania, USA

Luann Ochs, MS

Vice President, Standards

Development

Tracy A. Dooley, BS, MLT(ASCP)

Staff Liaison

Marcy Hackenbrack, MCM,

M(ASCP)

Project Manager

Melissa A. Lewis, ELS

Editorial Manager

Megan P. Larrisey, MA

Assistant Editor

Acknowledgment

CLSI and the Consensus Committee on Microbiology gratefully acknowledge the following individuals for their help in preparing this document:

Bernard M. Branson, MD

Centers for Disease Control and Prevention

Atlanta, Georgia, USA

Patricia E. Garrett, PhD

SeraCare Life Sciences, Inc.

Portland, Maine, USA

Renée M. Howell, PhD

Canon US Life Sciences, Inc.

Rockville, Maryland, USA

Contents

Abstract.....i

Committee Membership..... iii

Foreword..... vii

1 Scope.....1

2 Standard Precautions.....1

3 Terminology.....1

 3.1 A Note on Terminology1

 3.2 Definitions2

 3.3 Abbreviations and Acronyms5

4 Background/Natural History/Virology6

 4.1 The Human Immunodeficiency Virus6

 4.2 Natural History and Response to Infection8

5 Initial Tests for HIV Infection10

 5.1 Introduction.....10

 5.2 Types of Initial Testing for HIV11

 5.3 Viral Detection Tests for Initial Testing16

 5.4 Selection of Initial Tests17

 5.5 Limitations of Initial Tests.....18

 5.6 Borderline Test Results.....18

 5.7 Commercially Available Initial Tests18

6 Supplemental HIV Tests18

 6.1 Western Blot18

 6.2 Line Immunoassays22

 6.3 Indirect Immunofluorescence Assay.....24

 6.4 Nucleic Acid Tests.....26

 6.5 Enzyme Immunoassay30

7 Special Situations.....31

 7.1 Acute HIV-1 Infections31

 7.2 HIV-1, Non-B, and HIV-2 Infection.....33

 7.3 HIV-1/HIV-2 Initial and Supplemental Testing in Pregnancy38

 7.4 Testing During Labor and Delivery, and Newborn Testing39

 7.5 HIV-1 Seroreversion or Incomplete Anti-HIV-1 Antibody Evolution39

 7.6 Recent Infection40

 7.7 Serological Testing in HIV Vaccine Trial Participants43

 7.8 Special Situations on Blood and Body Fluid Exposures.....43

 7.9 Home Testing.....44

8 Algorithms44

 8.1 Algorithm I: Single Initial Antigen/Antibody Combination Immunoassay45

 8.2 Algorithm II: HIV-1/HIV-2 Antibody Immunoassay With HIV-1 Supplemental Tests47

Contents (Continued)

8.3	Algorithm III: Sequential HIV Antibody Immunoassay for Presumptive Diagnosis	49
8.4	Algorithm IV: Sequential HIV Antibody Immunoassays With Initial Oral Fluid Specimen.....	51
8.5	Algorithm V: Initial HIV Antigen/Antibody Discriminatory Immunoassay.....	53
8.6	Algorithm VI: Acute HIV Infection Testing.....	55
8.7	Resolution of Inconclusive or Persistently Indeterminate Results.....	57
9	Test Results and Reporting	57
9.1	Initial Tests	57
9.2	Supplemental Tests	58
9.3	Notification of Significant Test Results.....	59
9.4	Requirements for Specimen Retention	60
10	HIV Testing Quality Control	60
10.1	Establishing a Quality Control Program	60
10.2	Types of Control Materials	66
10.3	Sources of Control Material.....	67
10.4	Proficiency Testing Programs.....	67
	References.....	68
	Appendix. Reporting Comments Suggested for Initial and Supplemental HIV Diagnostic Test Results	79
	The Quality Management System Approach.....	88
	Related CLSI Reference Materials	89

Foreword

Since the advent of human immunodeficiency virus (HIV) testing, laboratory-based methods have undergone tremendous change. The routine use of nucleic acid tests, the introduction of antigen-antibody combination tests, and the widespread implementation of rapid testing methods, including the use of different specimen types, have changed the way HIV infection is diagnosed. Although these tests may offer improved sensitivity, specificity, and more rapid turnaround times, clinicians and laboratorians are asked to determine which tests to perform and how to best interpret the results.

There is increasing momentum to establish universal routine testing programs for HIV infection in order to limit the spread of infection and to identify individuals who may benefit from earlier initiation of antiviral therapy. In 2006, the Centers for Disease Control and Prevention issued a recommendation for routine HIV screening of all patients in the health care setting.¹ Concurrent with these recommendations, laboratorians and clinicians have used a number of new tests and testing strategies to diagnose HIV infection. Although there is an increased demand to use these tests, adequate consensus guidelines have not been proposed to assist in the appropriate use and interpretation of these tests and testing strategies.

This guideline was developed to provide an extensive review of existing laboratory methods commonly used to test for HIV infection and offer recommendations for how to best use and interpret these tests to accurately establish the diagnosis of HIV infection and effectively report these results to health care providers. This guideline is intended for use in the diagnosis of HIV-1 and HIV-2 infection in advanced diagnostic laboratories and point-of-care settings, and may not be applicable in resource-limited settings.

Key Words

Algorithms, differentiation testing, enzyme immunoassay, HIV initial testing, HIV supplemental testing, HIV-1, HIV-2, immunofluorescence assay, line immunoassay, nucleic acid testing, Western blot

Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection; Approved Guideline

1 Scope

This document provides an overview of the natural history and response to human immunodeficiency virus (HIV) infection, an in-depth review of initial and supplemental tests for the diagnosis of HIV infection, and initiation of a quality control (QC) program for HIV testing. This guideline also addresses special situations that commonly confound HIV testing, including the diagnosis of acute and recent HIV infection, initial and supplemental testing during pregnancy, labor and delivery, and newborn testing. Special attention is also given to testing for HIV-1, non-B subtype, and HIV-2 testing. In addition, diagnostic testing algorithms are provided to assist clinicians and laboratorians in the stepwise use of these tests, as well as a framework for additional testing and the interpretation of results. Furthermore, reporting criteria for commonly obtained test results are also provided.

This guideline is intended for use in the laboratory diagnosis of HIV infection in the health care setting, and does not address methods or strategies for screening the blood supply or organ or tissue donation. Furthermore, this guideline is not intended for use outside the clinical setting and does not address issues for diagnosing HIV from nonhuman material, environmental surfaces, or postmortem. Although some of the proposed tests and testing strategies may be universally applicable, the guidelines are primarily intended for advanced diagnostic laboratories, and may not address testing methods or strategies in more resource-limited settings.

2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the Centers for Disease Control and Prevention (CDC).² For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.³

3 Terminology

3.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization whenever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, International Organization for Standardization (ISO), and European Committee for Standardization (CEN) documents; and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. In light of this, CLSI’s consensus process for development and revision of standards and guidelines focuses on harmonization of terms to facilitate the global application of standards and guidelines.